Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genome-guided targeted therapy versus maintenance chemotherapy in metastatic breast cancer
2013-001652-36Phase 2Active
- Sponsor
- Unicancer
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vistusertib, fexagratinib, capivasertib, sapitinib, selumetinib and 3 more in breast cancer (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Jan 2014; status: active.
02
Drugs
vistusertibfexagratinibcapivasertibsapitinibselumetinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001652-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001652-36.